Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) - USD ($)		3 Months Ended			9 Months Ended		12 Months Ended
	Oct. 05, 2023	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jun. 27, 2024	Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax		$ 1,957,500		$ 397,060	$ 2,678,013	$ 2,212,271
Alphazyme [Member]
Proceeds from Sale, Maturity and Collection of Investments			$ 60,977				$ 1,300,000
Alphazyme [Member]
Ownership Percentage									1.99%
Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		532,500		352,942	1,253,013	2,079,918
Proliant Agreement [Member]
Initial Up Front Payment								$ 500,000
Second Payment Upon Completion Transfer								500,000
Final Payment Upon Meeting Certain Productivity Threshold								$ 500,000
Revenue from Contract with Customer, Excluding Assessed Tax		1			1
Inzymes Agreement APS [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		0			25,000
Non-refundable Upfront Payment, Received	$ 600,000
Revenue From Contract With Customer, License Agreement Milestone Payment		425,000
A Global Food Ingredient Company [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		0			0
A Global Food Ingredient Company [Member] | Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				0		565,000
A Global Food Ingredient Company [Member] | Success Fees [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				65,500		65,500
Janssen Pharmaceutical Companies [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 0		127,000	$ 0	507,000
Deferred License Revenue				$ 44,000		$ 132,000